Symbol="INBX"
AssetType="Common Stock"
Name="InhibrxÂ Inc"
Description="Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla, California."
CIK="1739614"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="11025 N. TORREY PINES ROAD, SUITE 200, LA JOLLA, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="686947000"
EBITDA="-142652992"
PERatio="None"
PEGRatio="None"
BookValue="1.333"
DividendPerShare="0"
DividendYield="0"
EPS="-3.68"
RevenuePerShareTTM="0.055"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.433"
ReturnOnEquityTTM="-7.67"
RevenueTTM="1280000"
GrossProfitTTM="-107994000"
DilutedEPSTTM="-3.68"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.982"
AnalystTargetPrice="48.2"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="255.62"
PriceToBookRatio="35.04"
EVToRevenue="276.69"
EVToEBITDA="-11.74"
Beta="2.713"
num_52WeekHigh="34.72"
num_52WeekLow="12.6"
num_50DayMovingAverage="24.08"
num_200DayMovingAverage="24.72"
SharesOutstanding="43615700"
DividendDate="None"
ExDividendDate="None"
symbol="INBX"
open="15.89"
high="16.20"
low="15.56"
price="15.90"
volume="248709.00"
latest_trading_day="2023-08-10"
previous_close="15.75"
change="0.15"
change_percent="0.9524%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="42"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="58"
Volume_recent_avg="360038"
Change_recent_avg="-0.08"
Delta_recent_avg="1.52"
Variance_recent_avg="0.76"
Change_ratio_recent_avg="-0.48"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="58"
Aroon_momentum_negative="42"
image_negative_thumbnail_id_1="506"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0099.jpeg"
image_negative_thumbnail_id_2="1164"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0198.jpeg"
image_neutral_thumbnail_id_1="596"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0003.jpeg"
image_neutral_thumbnail_id_2="570"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0029.jpeg"
image_positive_thumbnail_id_1="645"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0063.jpeg"
image_positive_thumbnail_id_2="964"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0126.jpeg"
image_professor_thumbnail_id_1="1176"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0010.jpeg"
image_professor_thumbnail_id_2="1187"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0021.jpeg"
